RGNT
Regentis Biomaterials Ltd. Ordinary Shares (RGNT)
Healthcare • AMEX • $2.22-2.63%
- Symbol
- RGNT
- Exchange
- AMEX
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Price
- $2.22
- Daily Change
- -2.63%
- Market Cap
- $11.50M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $8.35
- 52W Low
- $2.01
- Analyst Target
- $10.00
- Dividend Yield
- N/A
- Beta
- N/A
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
Company websiteResearch RGNT on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.